Rufloxacin is a fluoroquinolone antibiotic.1 It is active against S. aureus, E. coli, P. aeruginosa, P. morganii, K. pneumoniae, and E. cloacae in vitro (MICs = 0.78, 0.78, 12.5, 1.56, <0.39, and <0.39 μg/ml, respectively).2 Rufloxacin inhibits M. luteus DNA gyrase with an IC50 value of 1.5 mM and inhibits DNA synthesis in S. aureus, E. coli, P. aeruginosa, K. pneumoniae, and E. cloacae (IC50s = 0.93, 1.03, 38.8, 0.55, and 0.66 μg/ml, respectively).3,1 Rufloxacin (50 mg/kg, p.o.) reduces bacterial burden in the spleen and liver in a mouse model of systemic S. typhimurium infection.4
1.Piddock, L.J.V., Panchal, S., and Norte, V.Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in Gram-negative and Gram-positive bacteriaJ. Antimicrob. Chemother.31(6)855-863(1993) 2.Cecchetti, V., Fravolini, A., Fringuelli, R., et al.Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acidsJ. Med. Chem.30(3)465-473(1987) 3.Fabbri, S., Broggini, M., Pagella, P., et al.The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961J. Antimicrob. Chemother.27(5)687-689(1991) 4.Bonina, L., Carbone, M., Mastroeni, P., et al.Effects of rufloxacin in Salmonella typhimurium infection in miceJ. Chemother.4(6)353-357(1992)